Your browser doesn't support javascript.
loading
NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitro and in vivo.
Namoto, Kenji; Baader, Clara; Orsini, Vanessa; Landshammer, Alexandro; Breuer, Eva; Dinh, Kieu Trinh; Ungricht, Rosemarie; Pikiolek, Monika; Laurent, Stephane; Lu, Bo; Aebi, Alexandra; Schönberger, Katharina; Vangrevelinghe, Eric; Evrova, Olivera; Sun, Tianliang; Annunziato, Stefano; Lachal, Julie; Redmond, Emily; Wang, Louis; Wetzel, Kristie; Capodieci, Paola; Turner, Jonathan; Schutzius, Gabi; Unterreiner, Vincent; Trunzer, Markus; Buschmann, Nicole; Behnke, Dirk; Machauer, Rainer; Scheufler, Clemens; Parker, Christian N; Ferro, Magali; Grevot, Armelle; Beyerbach, Armin; Lu, Wei-Yu; Forbes, Stuart J; Wagner, Jürgen; Bouwmeester, Tewis; Liu, Jun; Sohal, Bindi; Sahambi, Sukhdeep; Greenbaum, Linda E; Lohmann, Felix; Hoppe, Philipp; Cong, Feng; Sailer, Andreas W; Ruffner, Heinz; Glatthar, Ralf; Humar, Bostjan; Clavien, Pierre-Alain; Dill, Michael T.
Affiliation
  • Namoto K; Biomedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: kenji.namoto@novartis.com.
  • Baader C; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland; University of Basel, Basel, Switzerland.
  • Orsini V; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Landshammer A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Breuer E; University Hospital Zurich (USZ), Zurich, Switzerland.
  • Dinh KT; German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Ungricht R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Pikiolek M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Laurent S; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Lu B; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Aebi A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Schönberger K; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Vangrevelinghe E; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Evrova O; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Sun T; Biomedical Research, Novartis Pharma AG, Basel, Switzerland; Division of Liver Diseases, Institute for Regenerative Medicine, Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Annunziato S; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Lachal J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Redmond E; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Wang L; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Wetzel K; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Capodieci P; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Turner J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Schutzius G; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Unterreiner V; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Trunzer M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Buschmann N; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Behnke D; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Machauer R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Scheufler C; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Parker CN; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Ferro M; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Grevot A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Beyerbach A; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Lu WY; University of Edinburgh, Center for Inflammation Research, Edinburgh, UK.
  • Forbes SJ; University of Edinburgh, Center for Regenerative Medicine, Edinburgh, UK.
  • Wagner J; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Bouwmeester T; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Liu J; Biomedical Research, Novartis Pharma AG, La Jolla, CA, USA.
  • Sohal B; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Sahambi S; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Greenbaum LE; Biomedical Research, Novartis Pharma AG, East Hanover, NJ, USA.
  • Lohmann F; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Hoppe P; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Cong F; Biomedical Research, Novartis Pharma AG, Cambridge, MA, USA.
  • Sailer AW; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Ruffner H; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Glatthar R; Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Humar B; University Hospital Zurich (USZ), Zurich, Switzerland.
  • Clavien PA; University Hospital Zurich (USZ), Zurich, Switzerland.
  • Dill MT; German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany; Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany.
Cell Stem Cell ; 31(4): 554-569.e17, 2024 Apr 04.
Article in En | MEDLINE | ID: mdl-38579685
ABSTRACT
The YAP/Hippo pathway is an organ growth and size regulation rheostat safeguarding multiple tissue stem cell compartments. LATS kinases phosphorylate and thereby inactivate YAP, thus representing a potential direct drug target for promoting tissue regeneration. Here, we report the identification and characterization of the selective small-molecule LATS kinase inhibitor NIBR-LTSi. NIBR-LTSi activates YAP signaling, shows good oral bioavailability, and expands organoids derived from several mouse and human tissues. In tissue stem cells, NIBR-LTSi promotes proliferation, maintains stemness, and blocks differentiation in vitro and in vivo. NIBR-LTSi accelerates liver regeneration following extended hepatectomy in mice. However, increased proliferation and cell dedifferentiation in multiple organs prevent prolonged systemic LATS inhibition, thus limiting potential therapeutic benefit. Together, we report a selective LATS kinase inhibitor agonizing YAP signaling and promoting tissue regeneration in vitro and in vivo, enabling future research on the regenerative potential of the YAP/Hippo pathway.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Serine-Threonine Kinases / Protein Kinase Inhibitors / YAP-Signaling Proteins Limits: Animals / Humans Language: En Journal: Cell Stem Cell / Cell stem cell (Online) Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein Serine-Threonine Kinases / Protein Kinase Inhibitors / YAP-Signaling Proteins Limits: Animals / Humans Language: En Journal: Cell Stem Cell / Cell stem cell (Online) Year: 2024 Type: Article